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Regulation of Neutrophilic Inflammation by
Proteinase-Activated Receptor 1 during Bacterial Pulmonary
Infection
Ricardo J. Jose´,1 Andrew E. Williams,1 Paul F. Mercer, Michal G. Sulikowski,
Jeremy S. Brown,2 and Rachel C. Chambers2
Neutrophils are key effector cells of the innate immune response to pathogenic bacteria, but excessive neutrophilic inflammation can
be associated with bystander tissue damage. The mechanisms responsible for neutrophil recruitment to the lungs during bacterial
pneumonia are poorly defined. In this study, we focus on the potential role of the major high-affinity thrombin receptor, proteinase-
activated receptor 1 (PAR-1), during the development of pneumonia to the common lung pathogen Streptococcus pneumoniae. Our
studies demonstrate that neutrophils were indispensable for controlling S. pneumoniae outgrowth but contributed to alveolar
barrier disruption. We further report that intra-alveolar coagulation (bronchoalveolar lavage fluid thrombin–antithrombin
complex levels) and PAR-1 immunostaining were increased in this model of bacterial lung infection. Functional studies using
the most clinically advanced PAR-1 antagonist, SCH530348, revealed a key contribution for PAR-1 signaling in influencing
neutrophil recruitment to lung airspaces in response to both an invasive and noninvasive strain of S. pneumoniae (D39 and
EF3030) but that PAR-1 antagonism did not impair the ability of the host to control bacterial outgrowth. PAR-1 antagonist
treatment significantly decreased pulmonary levels of IL-1b, CXCL1, CCL2, and CCL7 and attenuated alveolar leak. Ab
neutralization studies further demonstrated a nonredundant role for IL-1b, CXCL1, and CCL7 in mediating neutrophil recruit-
ment in response to S. pneumoniae infection. Taken together, these data demonstrate a key role for PAR-1 during S. pneumoniae
lung infection that is mediated, at least in part, by influencing multiple downstream inflammatory mediators. The Journal of
Immunology, 2015, 194: 6024–6034.
L
ower respiratory tract infections are a leading cause
of morbidity and mortality and represent an enormous
global healthcare burden (1). Infection with Streptococcus
pneumoniae is the predominant cause of pneumonia and conse-
quently one of the most common causes of death associated with
infectious disease worldwide (2, 3). Bacterial pneumonia in
humans is often accompanied by a pronounced inflammatory re-
sponse, characterized by an acute phase reaction, the release of
proinflammatory mediators, a heightened procoagulant state, and
the recruitment of large numbers of neutrophils to the lung (4–6).
This response is important for the control of bacterial infection
(7–10), but excessive neutrophilic inflammation can also lead to
bystander tissue damage, characterized by disruption of the al-
veolar barrier, pulmonary edema, and severely compromised
lung function (11, 12).
The local activation of coagulation within the intra-alveolar
compartment is a key feature of the pulmonary response to injury
and infection (13). The major high-affinity thrombin receptor,
proteinase-activated receptor 1 (PAR-1), has been shown to play
a central role in mediating the interplay between coagulation and
inflammation. PAR-1 activation is initiated via the proteolytic
unmasking of an N-terminal tethered ligand, which in turn binds to
the second extracellular loop to initiate cell signaling via the re-
cruitment of heterotrimeric G proteins (13, 14). PAR-1 signaling has
been shown to contribute to the pathogenesis of pulmonary fibrosis
and acute lung injury in experimental models (15, 16). However, the
contribution of PAR-1 signaling during pulmonary bacterial infec-
tion remains poorly defined, particularly during the acute phase of
the neutrophilic inflammatory response to S. pneumoniae.
To investigate the extent that neutrophils contribute to alveolar
barrier disruption during pulmonary bacterial infection, we used
a mouse model of S. pneumoniae challenge. The interplay between
PAR-1, neutrophilic inflammation, and alveolar leak was investi-
gated using a potent, highly selective and clinically advanced
PAR-1 antagonist, SCH530348 (17–19), in mice challenged with
both an invasive and noninvasive strain of S. pneumoniae. To
characterize the inflammatory mediators that may be regulating
neutrophil recruitment and pulmonary inflammation downstream
of PAR-1 signaling, we measured several proinflammatory cyto-
kines and chemokines following PAR-1 antagonist treatment. Ab
neutralization studies confirmed that several cytokines and che-
mokines were involved in regulating neutrophil recruitment during
S. pneumoniae infection. Finally, the effect of PAR-1 antagonism
on the control of bacterial outgrowth was also investigated. Taken
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together, our findings reveal a key role for PAR-1 in influencing
neutrophil recruitment and alveolar barrier disruption during
pneumococcal pneumonia, with potential important implications
for the treatment of excessive inflammation in this disease setting.
Materials and Methods
Ethics statement
All animal studies were performed according to the UK Home Office
Animals Scientific Procedures Act. Mice were kept in a specified pathogen-
free facility at University College London and housed in individually
ventilated cages, with free access to food and water.
Bacterial growth conditions and culture
S. pneumoniae (serotype 2 [D39] or 19F [EF3030]) was cultured on plates
containing Columbia agar (Oxoid, Basingstoke, U.K.) and 5% defribri-
nated horse blood (TCS Biosciences, Buckingham, U.K.) or in Todd–
Hewitt medium (THY, Oxoid) containing 5% yeast extract at 37˚C in the
presence of 5% CO2. Growth in medium was assessed by measuring the
OD at 580 nm with a spectrophotometer (Amersham Pharmacia Biotech,
Little Chalfont, U.K.). Bacterial stocks were grown to midlog phase (OD at
580 nm, 0.4–0.5) before being mixed in 10% glycerol and frozen at280˚C
in single-use aliquots. Bacterial counts (CFU) were calculated by plating
serial dilutions of the bronchoalveolar lavage (BAL) fluid, whole-lung
homogenate suspensions, or blood onto blood agar plates and incubated
for 18 h at 37˚C with 5% CO2.
Bacterial strain, infection model, cell isolation, and analysis
Female BALB/c mice (Harlan Laboratories, Bicester, U.K.), 7–8 wk of age,
were anesthetized with 5% isoflurane and each mouse was inoculated in-
tranasally with 50 ml containing 5 3 106 CFU S. pneumoniae serotype 2
(D39 strain), unless otherwise stated. In confirmatory experiments of the
effect of SCH530348 on host defense, mice were challenged with
S. pneumoniae 19F (EF3030). Mice were culled at 4, 24, or 48 h and BAL
fluid, whole lungs, and blood were removed postmortem. BAL fluid,
whole-lung homogenates, and blood samples were collected and prepared
for analysis as previously described (16, 20).
PAR-1 antagonists and in vivo infection model
The potent and highly selective PAR-1 antagonist, SCH530348, a synthetic
tricyclic 3-phenylpyridine analog of himbacine with the chemical name of
ethyl[(R1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-
pyridinyl]ethenyl]-dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]
carbamate was originally developed by Shering-Plough (17). Compound
for all studies was sourced from Axon Medchem (Groningen, The Neth-
erlands) as product number 1755. The compound was dissolved in vehicle
(30% Solutol; macrogol 15 hydroxystearate, polyoxyl 15 hydroxystearate
[Kolliphor HS 15, Sigma-Aldrich, Dorset, U.K.] in sterile double distilled
H2O) and the dose of SCH530348 was determined according to published
pharmacokinetic data in rodent models (17).
RWJ58259 is a specific PAR-1 antagonist (aS)-N-[(1S)-3-amino-1-
[[(phenylmethyl)amino]carbonyl]propyl]-a-[[[[1-(2,6-dichlorophenyl)
methyl]-3-(1-pyrrolidinylmethyl)-1H-indazol-6-yl]amino]carbonyl]
amino]-3,4-difluorobenzenepropanamide and the dose was used as previ-
ously described (16).
Mice were challenged with an intranasal inoculation of S. pneumoniae
(D39 or EF3030; ∼5 3 106 CFU) or sterile PBS and immediately treated
with vehicle (30% Solutol; macrogol 15 hydroxystearate, polyoxyl 15
hydroxystearate [Kolliphor HS 15, Sigma-Aldrich] in sterile double dis-
tilled H2O) or the PAR-1 antagonist SCH530348 (10 mg/kg) in vehicle by
i.p. injection. The number of bacteria administered was determined by
plating the inoculum used for each experiment. In separate experiments,
mice were treated with the vehicle or the PAR-1 antagonist every 12 h and
culled at either 4, 24, or 48 h, and BAL fluid, whole-lung tissue, and blood
were removed postmortem.
Immunohistochemistry and image analysis
The immunohistochemistry method was followed as described previously
(16). Briefly, mouse lungs were inflated with 10% neutral buffered for-
malin (Sigma-Aldrich) and fixed for 24 h at room temperature in 10%
neutral buffered formalin. Serial paraffin-embedded sections (4 mm) were
de-waxed and Ags were unmasked by microwaving sections with 10 mM
sodium citrate buffer (pH 6.0) for PAR-1 and S. pneumoniae staining. Ag
retrieval was omitted for the Ly6G neutrophil-specific marker. Endogenous
peroxide activity was blocked with 3% hydrogen peroxide (Sigma-
Aldrich) and sections were also blocked with 3% goat serum with 1%
BSA (Merck, Darmstadt, Germany) in PBS prior to incubation with pri-
mary Abs. Primary Abs to PAR-1 (0.8 mg/ml, Santa Cruz Biotechnology,
sc-5605), Ly6G (2 mg/ml, BD Biosciences, 551459), and pneumococcal
anti-serotype 2 D39 (dilution 1:20,000, Staten Institute, 16745) were in-
cubated for 16 h at 4˚C. IgG controls (Vector Laboratories, Orton South-
gate, U.K.) were included as a negative control. The following day,
sections were incubated for 30 min with biotin-labeled secondary Abs
(Vector laboratories) followed by 30 min incubation with ABC complex
(Vector Laboratories). Color was developed with diaminobenzidine chro-
mogen (BioGenex) for 5 min. Sections were counterstained with Gill II
hematoxylin, dehydrated, and permanently coverslipped. Slides were
digitally scanned using a NanoZoomer (Hamamatsu) at the 320 objective
size. Automatic quantitation of immunostained tissue sections was per-
formed using Definiens Tissue Studio (version 3.6). Three algorithms were
set up for each of the Ab markers used based on the chromogenic dia-
minobenzidine staining pattern, including 1) positive index for anti-Ly6G
Ab staining (neutrophils) defined as the ratio of all positively stained
neutrophils detected by immunohistochemistry to all nuclei stained with
blue hematoxylin for each individual scan; 2) percentage of anti–
S. pneumoniae capsular serotype 2 Ab staining; and 3) percentage and
intensity of anti–PAR-1 immunostaining (classified as weak, medium, and
high). The magnification and resolution of digitally scanned sections with
the Hamamatsu NanoZoomer (.ndp file) was automatically read by the
Definiens software. The analysis was blinded to treatment groups
throughout this analysis. Image analysis was carried out using the Defin-
iens algorithm corresponding to a310 objective, which created the grid on
the whole scans and defined each tile of the heat maps. A 310 objective
was employed to provide an ideal ratio between image resolution and lung
area sampled. The tiles that did not contain tissue (outside of region of
interest) were excluded from the analysis.
Neutrophil depletion
Ly6G+ neutrophils were depleted as previously described (21). Briefly, 600
mg anti-Ly6G mAb (clone 1A8, Bio X Cell) was administered by i.p.
injection in a volume of 200 ml 24 h prior to S. pneumoniae challenge.
Control mice were given 600 mg isotype control IgG2 Ab (clone 2A3, Bio
X Cell). Neutrophil depletion was confirmed by counting cells in the BAL
fluid and by demonstrating with flow cytometry a marked reduction in
anti-GR1+ cells in whole-lung homogenates (data not shown) of mice
challenged with S. pneumoniae.
Protein, cytokine, and chemokine analysis
Analysis of endothelial–epithelial barrier permeability was performed by
measuring mouse serum albumin in recovered BAL fluid by ELISA
according to the manufacturer’s instructions (Bethyl Laboratories). Co-
agulation activation was determined by measuring thrombin–antithrombin
complexes (TAT) in BAL fluid by ELISA (EIAab). Cytokines (IFN-g, IL-
1b, IL-6, IL-10, and TNF) and chemokine (KC/Gro) were measured with
the mouse proinflammatory 7-plex ultra-sensitive kit (Meso Scale Dis-
covery, Rockville, MD) according to the manufacturer’s protocol. The
chemokine CCL2 (MCP-1) was measured by ELISA (R&D Systems
Europe) or the mouse CCL2 ultra-sensitive kit (Meso Scale Discovery)
according to the manufacturer’s protocol, and CCL7 (MCP-3) was mea-
sured by ELISA (PromoKine) according to the manufacturer’s protocol.
In vivo neutralization of bronchoalveolar cytokines and
chemokines
Mice were intranasally challenged with sterile PBS or S. pneumoniae D39
(5 3 106 CFU, 50 ml). Additionally, the inoculum contained 10 mg neu-
tralizing Ab per mouse (anti-CXCL1, PeproTech, London, U.K.; anti-
CCL2, R&D Systems Europe; anti-CCL7, PeproTech; or anti–IL-1b,
Thermo Fisher Scientific, Leicestershire, U.K.) or poly-IgG control
(PeproTech) (16). Additionally, in a separate experiment anti-CXCL1
(PeproTech) was administered i.p. 2 h before S. pneumoniae challenge
as previously described (22). Animals were culled at 4 h postchallenge and
BAL fluid, whole-lung tissue, and blood were removed postmortem.
Statistical analysis
Data were analyzed using Graphpad Prism version 6. Data were statistically
compared by a Student t test for the comparison of two groups. The
comparison of more than two groups was made by one-way or two-way
ANOVAwith a Holm–Sidak post hoc test as appropriate. Correlations were
analyzed with Pearson correlation coefficients. All p values are two-tailed
and were considered significant when p , 0.05.
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Results
Neutrophil recruitment is required for host defense to
S. pneumoniae but disrupts alveolar barrier integrity
We first characterized the neutrophilic response during bacterial
infection in our model of S. pneumoniae pneumonia (serotype 2;
D39, 5 3 106 CFU/ml intranasally, in BALB/c female mice 7–8
wk old). Immunohistochemical analysis of Ly6G+ neutrophils
revealed that neutrophil accumulation was significantly increased
at the earliest time point examined (4 h) and was further increased
24 h postinfection (Fig. 1A, 1B). Furthermore, we performed
immunostaining for S. pneumoniae (pneumococcal anti-serotype
2, D39) to determine the colocalization of bacteria with neu-
trophils (Fig. 1C). Heat maps of immunostaining intensity gener-
ated by quantitative image analysis (based on algorithms generated
using Definiens software) of multiple serial sections confirmed that
neutrophils were recruited predominantly to sites of S. pneumoniae
localization (Fig. 1D).
We next determined the contribution of neutrophil recruitment
to alveolar barrier disruption following S. pneumoniae challenge.
Mice were injected with an anti-Ly6G Ab to deplete neutrophils
prior to lung infection. The number of neutrophils recovered from
BAL fluid at 24 h was reduced by 95% compared with S. pneu-
moniae–infected mice treated with a control IgG Ab (Fig. 2A,
2B). Neutrophil depletion was accompanied by a significant re-
duction in BAL fluid albumin levels compared with IgG control
Ab–treated mice (Fig. 1C). These albumin levels were similar to
the levels measured in PBS only–challenged mice (mean 6 SEM,
190 6 18.87 mg), indicating that neutrophils contribute to the
disruption of the alveolar barrier during S. pneumoniae infec-
tion. However, neutrophil depletion also resulted in increased
S. pneumoniae CFU recovered from the BAL fluid, whole-lung
homogenates, and blood (Fig. 2D–F), indicating that neutrophils
play an indispensable role in controlling bacterial outgrowth in
this model.
PAR-1 expression and coagulation activation are increased
following S. pneumoniae infection
We next investigated whether PAR-1 is involved in the host re-
sponse to S. pneumoniae infection. We first examined PAR-1
expression by immunohistochemistry in serial lung sections.
PAR-1 immunostaining in the lung at baseline was prominent for
multiple cell types, including bronchiolar and alveolar epithelium,
endothelium, and macrophages (Fig. 3A). PAR-1 staining inten-
sity was increased in S. pneumoniae–infected mice at 24 h. In-
creased PAR-1 expression in S. pneumoniae–infected mice at 24 h
was confirmed by quantitative image analysis (based on algo-
rithms generated using Definiens software) (Fig. 3B).
Because PAR-1 is the major high-affinity receptor for thrombin
and other key enzymes of the extrinsic coagulation cascade, we
FIGURE 1. Characterization of neutrophil re-
cruitment and S. pneumoniae infection in BALB/c
mice. BALB/c mice (7–8 wk old) were challenged
intranasally with S. pneumoniae D39 (53 106 CFU)
or PBS and culled at 4 h and 24 h for (A) immu-
nohistochemistry of lung sections at 24 h stained
with a specific Ly6G Ab and counterstained with
hematoxylin. Original magnification 310; inset,
340. (B) Quantification of Ly6G staining at 4 and
24 h on lung sections from PBS-challenged and
S. pneumoniae–infected mice. (C) Immunohistochem-
istry for S. pneumoniae serotype 2 on lung sections
at 24 h from mice challenged with S. pneumoniae
(original magnification 310; inset, 340, counter-
stained with hematoxylin) and (D) heat maps rep-
resentative of Ly6G and S. pneumoniae staining
intensity at 24 h. Data are expressed as bar graphs
with means6 SEM (n = 6/group) and analyzed with
the unpaired Student t test and two-way ANOVA
with a Holm–Sidak post hoc test.
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next assessed coagulation activation during S. pneumoniae infec-
tion by measuring TAT levels in BAL fluid. S. pneumoniae in-
fection significantly increased TAT levels at 4 and 24 h (Fig. 3C)
compared with PBS-challenged mice, suggesting the presence
of a procoagulant state in this model. The levels of TAT in
S. pneumoniae–infected mice decreased over time, suggesting that
maximal coagulation activation occurred early following infec-
tion.
PAR-1 promotes neutrophil recruitment and alveolar leak
following S. pneumoniae infection
The potential functional role of PAR-1 in S. pneumoniae–induced
neutrophil recruitment was next investigated by treating mice with
the PAR-1 antagonist SCH530348 (10 mg/kg, i.p.) or drug vehicle
alone. Total BAL fluid cell counts increased by 6- and 8-fold in
S. pneumoniae–infected mice at 4 and 24 h, respectively. PAR-1
antagonist treatment was associated with a significant reduction in
BAL fluid total cell counts (by ∼43%) and neutrophil counts
(∼73%) at 4 h, compared with drug vehicle-treated mice (Fig. 4A,
4C). The therapeutic effect of SCH530348 was maintained at 24 h
(Fig. 4B, 4D), but the magnitude of the inhibitory effect was
reduced at this time point. The effect of PAR-1 antagonism
on neutrophil recruitment to airspaces was confirmed in the
same model using a second small molecule PAR-1 antagonist,
RWJ58259 (Supplemental Fig. 1), and in mice infected with a less
invasive S. pneumoniae strain, EF3030 (Supplemental Fig. 2).
PAR-1 antagonism in mice infected with S. pneumoniae EF3030
was associated with a reduction in neutrophil counts in the air-
spaces at 4 and 24 h, but this reduction was only statistically
significant at 4 h. Taken together, these data led us to conclude that
PAR-1 contributes to the recruitment of neutrophils into the al-
veolar space during S. pneumoniae pneumonia. Additionally, we
determined the percentage of neutrophils (Ly6GhiF4/802CD11bhi
cells) in the BAL fluid and whole-lung homogenates of mice
treated with the PAR-1 antagonist or vehicle at 4 h following
S. pneumoniae challenge (Fig. 4E, 4F). PAR-1 antagonism
resulted in a significant reduction in the proportion of neu-
trophils recruited to the airspaces, whereas the percentage of
neutrophils in whole-lung homogenates increased compared with
vehicle-treated mice, suggesting that PAR-1 antagonism resulted
in neutrophil retention in the pulmonary vasculature or lung pa-
renchyma.
We next investigated the role of PAR-1 in regulating alveolar
barrier function during S. pneumoniae infection by measuring
BAL fluid albumin levels. BAL fluid albumin levels were signif-
icantly increased 24 h following S. pneumoniae infection. This
increase was significantly reduced by PAR-1 antagonism (Fig. 4E).
Moreover, there was a strong positive correlation (r = 0.7270, R2 =
0.5285, p = 0.0074) between BAL fluid neutrophil counts and BAL
fluid albumin levels (Fig. 4F), further supporting the conclusion that
neutrophil recruitment is associated with increased alveolar leak
during S. pneumoniae infection.
PAR-1 regulates early inflammatory cytokines and chemokines
To delineate the potential mechanism by which PAR-1 influences
neutrophil recruitment during S. pneumoniae infection, we mea-
sured the pulmonary levels of several key proinflammatory cyto-
kines and chemokines at 4 h. This time point was chosen on the
basis that this is the time point at which TAT levels are maximally
increased in this model and at which the PAR-1 antagonist exerted
its maximal inhibitory effect on neutrophil recruitment. The levels
of TNF and IL-6 were increased in response to S. pneumoniae
infection, and although these levels were attenuated in response to
PAR-1 antagonist treatment, this was not statistically significant
(Fig. 5A, 5B). The increase in the levels of IFN-g and IL-10 were
not affected (Fig. 5C, 5D). In contrast, PAR-1 antagonist treatment
significantly attenuated the elevated lung levels of the canonical
proinflammatory cytokine IL-1b (Fig. 5E) and the chemokines
CXCL1, CCL2, and CCL7 (Fig. 5F–H) following S. pneumoniae
infection. Taken together, these data suggest that PAR-1 may in-
fluence neutrophil recruitment by regulating the levels of several
proinflammatory cytokines and chemokines.
FIGURE 2. Neutrophil depletion protects mice
from alveolar leak but compromises host defense.
BALB/c mice (7–8 wk old) were treated with anti-
Ly6G or anti-IgG (control Ab) 24 h prior to being
challenged intranasally with S. pneumoniae D39 (53
106 CFU). Mice were culled at 24 h postinfection.
(A) Representative cytospins of cells recovered from
BAL fluid (Romanowski stain; original magnification
340) and (B) neutrophil counts. (C) Albumin levels
recovered from BAL fluid 24 h following infection
were measured as a marker of alveolar leak. Bacterial
CFU recovered from (D) BAL fluid, (E) lung
homogenates, and (F) blood were measured 24 h
following infection.
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IL-1b, CXCL1, and CCL7 mediate neutrophil recruitment to
the airspaces in different pulmonary compartments
We next assessed the contribution of IL-1b, CXCL1, CCL2, and
CCL7 to the recruitment of neutrophils during S. pneumoniae
pneumonia using specific neutralizing Abs administered intrana-
sally. Assessment of BAL fluid cytokine levels confirmed that this
Ab neutralization strategy resulted in nearly complete neutrali-
zation of each of these mediators in response to S. pneumoniae
infection (Fig. 6A–D). Intra-alveolar neutralization of either IL-1b
or CCL7 resulted in significant reductions (∼52 and ∼77%, re-
spectively) in the number of neutrophils recruited to the airspaces
in S. pneumoniae–challenged mice (Fig. 6E, 6F). In contrast,
intra-alveolar neutralization of either CXCL1 or CCL2 had no
effect (Fig. 6G, 6H).
CXCL1 is a major classical neutrophil chemoattractant in mice
(23). We therefore also examined the effect of the anti-CXCL1 Ab
given via systemic delivery (i.p. injection). Systemic neutraliza-
tion of CXCL1 resulted in a 55% reduction (p = 0.0341) in
neutrophil accumulation in the airspaces in response to S. pneu-
moniae infection (Fig. 6I), demonstrating a potential role for this
chemokine within the vascular compartment.
Finally, to rule out the potential possibility that the attenuated
neutrophil responses in mice treated with either anti–IL-1b, anti-
CXCL1, or and anti-CCL7 Abs might be related to a reduction in
bacterial load, we also measured the BAL and lung S. pneumo-
niae CFU. These were found to be similar for anti-CXCL1–,
anti-CCL7–, and anti-CCL2 –treated mice (Supplemental Fig.
3A–C, 3E), or even slightly higher in the case of anti–IL-1b-
treated mice (Supplemental Fig. 3D) compared with mice given
IgG control Abs. Hence, a reduction in bacterial load is unlikely
to explain the reduction in neutrophil accumulation observed in
Ab-treated mice.
PAR-1 antagonism does not compromise host defense
Having demonstrated that PAR-1 influences neutrophil recruitment
by regulating the pulmonary levels of several cytokines and che-
mokines, we next evaluated the effect of PAR-1 antagonism on host
defense by measuring S. pneumoniae CFU recovered from BAL
fluid (Fig. 7A), lung homogenates (Fig. 7B), and blood (Fig. 7C).
The CFU recovered in BAL fluid and lung homogenates was
highest at 4 h and declined at 24 and 48 h. In contrast, blood CFU
increased over time. At all time points examined, we found that
there were no differences in BAL fluid, lung, and blood S. pneu-
moniae CFU between mice treated with the PAR-1 antagonist or
the drug vehicle (4, 24, and 48 h; Fig. 7A–C), indicating that
antagonizing PAR-1 reduces neutrophil recruitment but does not
appear to compromise the ability of the host to control bacterial
FIGURE 3. PAR-1 expression and coagulation
activation is increased following S. pneumoniae
infection. BALB/c mice (7–8 wk old) were chal-
lenged intranasally with S. pneumoniae D39 (5 3
106 CFU) or PBS and culled at 4 h or 24 h. (A)
Immunohistochemistry staining for PAR-1 on lung
sections from mice challenged with PBS and
S. pneumoniae 24 h postinfection (original mag-
nification 310; inset, 340; IgG, negative control;
counterstained with hematoxylin). (B) Quantifica-
tion of PAR-1 staining intensity in lung sections at
4 and 24 h for mice challenged with PBS or
infected with S. pneumoniae. (C) TAT complexes
were measured by ELISA. Data are expressed as
bar graphs with means 6 SEM (n = 3–6/group)
and analyzed with two-way ANOVAwith a Holm–
Sidak post hoc test.
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outgrowth. This finding was further confirmed using a second
PAR-1 antagonist (RWJ58259) (Supplemental Fig. 1). The effect
of PAR-1 antagonism on host defense was also assessed using the
EF3030 S. pneumoniae noninvasive pneumonia model (Fig. 7D),
which has previously been shown to cause bacteremia when host
defense is compromised (10, 24). Treatment with SCH530348 did
not result in increased recovery of EF3030 S. pneumoniae CFU
from BAL fluid at 4, 24, and 48 h. Additionally, mice did not
develop bacteremia at any of these time points, indicating that
despite the reduction in neutrophil recruitment, PAR-1 antagonism
did not lead to invasive infection with this pathogen.
Discussion
Infection with S. pneumoniae is characterized by a pronounced
neutrophilic inflammatory response, an intra-alveolar procoagu-
lant state, and disruption of the alveolar epithelial barrier leading
to the leakage of protein-rich fluid into the alveolar space and
pulmonary edema. However, the extent to which neutrophils
contribute to alveolar leak, as well as the interplay between in-
flammation and coagulation, remains poorly characterized. We
now demonstrate that neutrophils are important for controlling
bacterial outgrowth, but they also promote alveolar barrier dis-
ruption. We further show that neutrophil recruitment is regulated
by the major high-affinity thrombin receptor, PAR-1, which is
upregulated following infection with S. pneumoniae. PAR-1 was
shown to regulate neutrophil accumulation by modulating the
expression of several proinflammatory cytokines, including IL-1b
and the chemokines CXCL1 and CCL7. Although the control of
bacterial outgrowth is dependent on neutrophils, modulating ex-
cessive neutrophilic inflammation by antagonizing PAR-1, or
neutralizing IL-1b, CXCL1, or CCL7, attenuates neutrophil re-
cruitment without affecting bacterial outgrowth. Taken together,
these studies reveal a previously unidentified mechanism that
mediates neutrophilic inflammation during pulmonary bacterial
infection.
Neutrophil recruitment into the lung is a multistep process in-
volving extravasation across the pulmonary endothelium, traf-
ficking across the lung interstitium, and migration across the
alveolar epithelium into airspaces. This involves multiple che-
motactic molecules acting at specific spatiotemporal checkpoints
(23). The microanatomy of the distal lung provides an unusual
environment for neutrophil migration, as sheer forces are low in
the narrow pulmonary capillary network so that neutrophils do not
undergo the classical rolling, slowing, and adhesion associated
with extravasation observed in other organs (23, 25). Furthermore,
it has been estimated that the pool of neutrophils sequestered
within the pulmonary microvasculature exceeds the size of the
circulating pool by ∼5-fold so that there is a large pool of intra-
pulmonary neutrophils that can be rapidly mobilized in response
to inflammatory insults and infection (23). However, the contri-
bution of neutrophils to barrier disruption during lung inflamma-
tion remains enigmatic, and current evidence suggests that it is
FIGURE 4. Neutrophil recruitment to the bronchoalveolar space and
alveolar barrier disruption are attenuated by PAR-1 antagonism following
S. pneumoniae infection. BALB/c mice (7–8 wk old) were challenged
intranasally with PBS or S. pneumoniae D39 (5 3 106 CFU) and treated
with either vehicle or the PAR-1 antagonist. Total cells recovered from
BAL fluid at (A) 4 and (B) 24 h following infection and the total number of
neutrophils recovered from BAL fluid were calculated (C) 4 and (D) 24 h
following infection. (E) Representative flow cytometry gating for the
identification of neutrophils (Ly6GhiF4/802CD11bhi) and (F) proportion of
neutrophils identified in BAL fluid and whole-lung homogenates at 4 h
following infection in mice treated with the PAR-1 antagonist or vehicle.
Furthermore, (G) BAL fluid albumin levels were measured by ELISA from
recovered BAL fluid at 24 h postchallenge. Data are expressed as bar
graphs with means 6 SEM (n = 4–6/group) and were analyzed with one-
way ANOVAwith a Holm–Sidak post hoc test. Scatter plot is shown with
linear regression line for neutrophil counts and albumin levels in (H) BAL
fluid at 24 h for mice challenged with S. pneumoniae and treated with
vehicle or the PAR-1 antagonist; data were analyzed with a Pearson cor-
relation coefficient and linear regression.
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highly dependent on both the nature and location of the primary
insult (23). In vitro studies employing lung epithelial cells support
the notion that neutrophils are capable of promoting epithelial
barrier disruption (26–28). This has also been confirmed in animal
models of pancreatitis-associated lung injury (29), lung reperfu-
sion injury (30), LPS-induced lung injury (31), and in the context
of hantavirus infection (32). However, other animal models of
lung injury suggest that alveolar barrier disruption is independent
of neutrophil recruitment (33–35). Both the contribution of neu-
trophils to alveolar leak and the mechanisms responsible for
neutrophil recruitment in the context of bacterial infection still
remain poorly defined. We now report that nearly complete neu-
trophil depletion significantly attenuated alveolar leak during
S. pneumoniae lung infection. To the best of our knowledge, this
represents the first in vivo evidence linking neutrophil recruitment
to disruption of the alveolar barrier during pulmonary S. pneu-
moniae infection. However, keep in mind that nearly complete
neutrophil depletion compromised the ability of the host to control
bacterial outgrowth (10). These observations are in line with the
notion that the recruitment of neutrophils to sites of lung infection
needs to be finely balanced so as to provide adequate host defense
without promoting bystander tissue damage.
The local intravascular activation of the coagulation cascade is
part of the normal response to lung injury and ensures that there is
limited blood loss in response to damage to the extensive lung
microvasculature. Additionally, there is evidence that tissue factor–
dependent coagulation within the intra-alveolar compartment also
promotes lung inflammatory and fibroproliferative responses in
the settings of acute and chronic lung injury via both fibrinogen-
dependent and fibrinogen-independent cellular responses (36–38).
Current evidence supports a role for the major high-affinity
thrombin-receptor, PAR-1, in mediating the interplay between
coagulation, inflammation, and tissue repair in both the lung and
other organs (15, 39). In uninjured lungs, PAR-1 is expressed by
multiple cell types, including alveolar macrophages, dendritic
cells, fibroblasts, bronchial and alveolar epithelium, and pulmo-
nary endothelium (14). Additionally, it is expressed on monocytes
and lymphocytes recruited to the lungs, but it is not expressed by
neutrophils (14). In the present study, we now report that PAR-1
immunostaining is increased during S. pneumoniae pneumonia,
most obviously in the endothelium and epithelium. The regulation
of PAR-1 expression in the lung is not fully understood; however,
a role for Rac1 in regulating surface expression of this receptor in
vascular smooth muscle cells has been identified (40), whereas
the transcription factors AP-2, specificity protein-1, early growth
response-1, and the tumor suppressor gene p53 have been shown
to regulate PAR-1 gene expression on numerous cell types (41,
42).
We now report that PAR-1 antagonism with the recently U.S.
Food and Drug Administration–approved (43), highly potent, and
FIGURE 5. PAR-1 antagonism reduces
inflammation in S. pneumoniae infection.
BALB/c mice (7–8 wk old) were challenged
intranasally with PBS and or S. pneumoniae
D39 (5 3 106 CFU), treated with either vehi-
cle or the PAR-1 antagonist, and culled at 4 h.
(A–F) Whole-lung homogenate levels of TNF,
IL-6, IL-1b, IL-10, IFN-g, and CXCL1 mea-
sured by multiplex ELISA (Meso Scale Dis-
covery) and (G and H) whole-lung homogenate
levels of CCL2 and CCL7 measured by
ELISA. Data are expressed as means 6 SEM
(n = 4–6/group). Data were analyzed with one-
way ANOVAwith a Holm–Sidak post hoc test.
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selective PAR-1 antagonist SCH530348 greatly attenuated pul-
monary neutrophil recruitment to the airspaces of S. pneumoniae–
infected mice. This finding was confirmed using a second struc-
turally unrelated selective PAR-1 antagonist, RWJ58259. Fur-
thermore, the reduction in neutrophil recruitment to airspaces was
associated with neutrophil retention in the pulmonary vasculature
or lung parenchyma, suggesting that antagonism of PAR-1 pre-
vents neutrophil transmigration across the endothelium or alveolar
epithelium. The exact mechanism remains to be elucidated, but
PAR-1 has been shown to regulate the expression of endothelial
cell adhesion molecules, such as ICAM-1 and VCAM-1, which in
turn may influence the migration of neutrophils into different
tissue microcompartments within the lung (44). PAR-1 antago-
nism was also associated with a significant reduction in alveolar
leak, again suggesting that neutrophils contribute to barrier dis-
ruption. Also, bear in mind that the attenuation in alveolar leak in
PAR-1 antagonist-treated mice might be a direct effect of PAR-1
on endothelial cells (45). PAR-1 plays an important role in regu-
lating endothelial barrier integrity and, depending on the nature
and concentration of the activating proteinase, it can be either
barrier disruptive or barrier-protective (14). Indeed, low thrombin
concentrations and activated protein C acting on PAR-1 can lead
to transactivation of the barrier-protective sphingosine-1 phos-
phate receptor-1 (46, 47), whereas high thrombin concentrations
and matrix metalloproteinase-1, also acting via PAR-1, increase
vascular permeability through activation of sphingosine-1 phos-
phate receptor-3 (48). Furthermore, the beneficial role of PAR-1 in
a model of lethal sepsis (induced in response to bacterial perito-
nitis by cecal ligation and puncture) has been shown to switch
during the progression of sepsis. Whereas early blockade of PAR-1
improves survival, late blockade was found to be detrimental to
the host (49). In our model of S. pneumoniae–induced pneumonia,
the beneficial effect of blocking PAR-1 leads to a prolonged re-
duction in neutrophil recruitment and alveolar leak, suggesting that
the role of PAR-1 in mediating inflammation and barrier disruption
is indeed highly context-dependent.
Additionally, note that the mode of PAR-1 inhibition might also
dictate outcome, as has been previously reported in the context of
cardiac remodeling and hypertrophy (50). In the present study, we
elected to investigate the role of PAR-1 following S. pneumoniae
infection by using a potent and highly selective PAR-1 antagonist
SCH530348 (18, 19), which has recently been approved by the U.S.
Food and Drug Administration for the treatment and prevention of
atherothrombotic events in postmyocardial infarction patients (43).
Our study revealed that PAR-1 inhibition resulted in an early (4 h)
and late (24 h) inhibition of neutrophil recruitment and lower levels
of proinflammatory mediators following challenge with S. pneumoniae
with no deleterious effects on bacterial outgrowth. This is in contrast
to observations reported for S. pneumoniae challenge in PAR-1
knockout (PAR-12/2) mice, which exhibit lower bacterial loads,
enhanced proinflammatory mediator levels, and only a late attenu-
ation of neutrophil recruitment (51). In terms of likely explanations
for these differences, it is possible that potential compensatory
pathways, including signaling via other PARs in PAR-12/2 mice, as
has been previously suggested in the context of embryonic devel-
opment (52) and cardiac remodeling in PAR-1–deficient animals
(50), might be critical. Differences in mouse (BALB/c versus
C57BL/6) and bacterial background strain (serotype 2 versus 3)
could also provide a potential explanation.
Because PAR-1 antagonism abrogated the recruitment of neu-
trophils into lung airspaces during S. pneumoniae infection, we
next sought to determine the potential role of PAR-1 in regulating
proinflammatory mediator levels. TNF and IL-1 are considered to
be two key early proinflammatory response cytokines induced
following infection. For example, previous studies using TNF
knockout mice have shown reduced neutrophil recruitment fol-
lowing S. pneumoniae infection (53). We now demonstrate that
PAR-1 antagonism only had a modest effect on TNF levels but
that it significantly reduced the expression of IL-1b. Furthermore,
neutralization of IL-1b resulted in reduced neutrophil accumula-
tion, suggesting that IL-1b is a key cytokine involved in modu-
lating the recruitment of neutrophils downstream of PAR-1.
FIGURE 6. Neutralization of broncholaveolar CCL7 and IL-1b in the alveolar compartment and systemic neutralization of anti-CXCL1 reduce neu-
trophil recruitment to the bronchoalveolar space. BALB/c mice (7–8 wk old) were challenged intranasally with 10 mg neutralizing Ab (anti–IL-1b, anti-
CCL7, anti-CCL2, and anti-CXCL1) and PBS or S. pneumoniae D39 (53 106 CFU) and culled at 4 h. (A–D) BAL fluid was recovered and the levels of IL-
1b, CCL7, CCL2, and CXCL1 were measured. Neutrophil counts in BAL fluid were determined from cytospin preparations and total cells counts for mice
treated intranasally with (E) anti–IL-1b, (F) anti-CCL7, (G) anti-CCL2, and (H) anti-CXCL1 and from mice treated with (I) anti-CXCL1 by i.p. injection.
Data are expressed as bar graphs with means 6 SEM (n = 5–6/group) and were analyzed with two-way ANOVA with a Holm–Sidak post hoc test.
The Journal of Immunology 6031
Indeed, previous studies have demonstrated a role for IL-1b sig-
naling in the recruitment of neutrophils in response to S. pneu-
moniae (53, 54).
In vitro studies in diverse cell types have demonstrated that PAR-1
is capable of engaging multiple signaling cascades and thereby
influences a variety of cellular responses, including regulating the
expression and release of inflammatory cytokines and chemokines
(14, 55, 56). In the present study, we provide evidence that PAR-1
antagonism also significantly reduced levels of CXCL1, CCL2,
and CCL7 in response to S. pneumoniae infection. Moreover,
intra-alveolar neutralization of the non–classical neutrophil che-
moattractant CCL7 attenuated neutrophil recruitment to alveolar
airspaces. However, intra-alveolar neutralization of the related
chemokine CCL2, as well as the classical neutrophil chemo-
attractant CXCL1, had no effect, despite evidence of effective
neutralization of these chemokines. The lack of an effect of anti-
CXCL1 on neutrophil recruitment was unexpected given that
previous studies using anti-CXCL1 Abs or CXCR2 knockout mice
support a role for this chemokine in neutrophil recruitment during
S. pneumoniae infection (10, 57). Indeed, in our model, subse-
quent studies revealed that the route of Ab administration was
a critical determinant of outcome in that systemic neutralization
by i.p. injection of anti-CXCL1 was found to be highly effective at
reducing neutrophil recruitment to airspaces. Taken together, these
data suggest that CXCL1 in the pulmonary vasculature, rather
than the local intra-alveolar compartment, might be important for
pulmonary neutrophil transmigration in this model. Furthermore,
CXCL1 and CCL7 may differentially influence neutrophil mi-
gration within discrete pulmonary compartments, such as the en-
dothelium, interstitium, and epithelium. However, these studies
highlight the contextual complexities of the pulmonary chemokine
network and the spatial and temporal compartmentalization within
the lung (23). Finally, the dynamic nature of host–pathogen
interactions also means that inherent interexperimental variation
can be a factor in animal models of bacterial infection, and
therefore any resulting data should be interpreted with this in
mind.
Our study also addressed the potential contribution of neutro-
philic inflammation to control bacterial outgrowth. Bacterial CFU
recovered in BAL fluid and whole-lung homogenates was highest at
4 h and declined at 24 and 48 h. The 4 h bacterial CFU likely
represents the initial bacterial inoculum. Bacterial CFU then
decreases by 24 h as the inoculated bacteria are cleared by the host
immune response. Nearly complete depletion of the neutrophil
population severely compromised host defense, indicating that
bacterial clearance is dependent on neutrophil recruitment into the
airspaces. Therefore, it was important for us to evaluate the effect of
PAR-1 antagonist treatment on bacterial clearance, considering the
significant reduction, but not complete abrogation, of neutrophil
numbers recovered in BAL fluid. Our data revealed that the at-
tenuated neutrophil response following PAR-1 antagonist treatment
was sufficient for the control of bacterial outgrowth with both
invasive and noninvasive strains of S. pneumoniae. This suggests
that reducing excessive neutrophilic inflammation does not nec-
essarily impair the ability of the host to control infection and that
only a small proportion of recruited neutrophils might be needed
to provide adequate protection.
Additionally, in experimental lung injury, airspace neutrophil ac-
cumulation has been associated with several physiological parameters
associated with disease severity (e.g., arterial oxygen saturation, re-
spiratory rate, and heart rate) (12), suggesting that attenuating neu-
trophil recruitment to the lungs without compromising host defense
could be clinically beneficial. This may be particularly relevant in
adult respiratory distress syndrome and other pulmonary conditions
associated with bacterial infection, including exacerbation of chronic
obstructive pulmonary disease, where bacterial infection may be
controlled by the use of antibiotics. Strategies aimed at controlling
neutrophilic inflammation and the resultant lung injury may therefore
represent potential complementary treatment options.
FIGURE 7. PAR-1 antagonism with SCH530348 does not compromise
host defense. BALB/c mice (7–8 wk old) were challenged intranasally with
PBS and treated with vehicle or challenged with S. pneumoniae D39 or
S. pneumoniae EF3030 (5 3 106 CFU) and treated with either vehicle or
the PAR-1 antagonist. Mice were culled at 4, 24, or 48 h. Bacteria were
cultured from recovered (A) BAL fluid, (B) whole-lung homogenates, and
(C) blood at 4, 24, and 48 h, respectively, for mice challenged with D39
and (D) BAL fluid at 4, 24, and 48 h for mice challenged with EF3030.
Data are expressed as dot plots with mean (n = 6–8/group) and analyzed
with a Student t test.
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In summary, the data reported in this study suggest a key role for
PAR-1 in the innate immune response to S. pneumoniae infection.
PAR-1 expression is increased in the lungs following challenge to
S. pneumoniae and contributes to the neutrophilic response by
influencing multiple downstream inflammatory mediators, in-
cluding IL-1b, CXCL1, and CCL7 within different lung com-
partments. Moreover, PAR-1 antagonism attenuated alveolar
barrier disruption without impairing host defense. Finally, al-
though further studies are needed to fully understand the role of
this receptor in different pneumonia models, to our knowledge, the
present study provides the first preclinical proof of concept that
PAR-1 antagonism may represent a potential novel therapeutic
approach for the prevention of excessive neutrophilic lung injury
associated with bacterial pneumonia.
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